MedTrace Logo

The Utility of PSADv (PSA Density Velocity) While on Dutasteride for Predicting Prostate Cancer Incidence and Grade and Stage

NCT01484808 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 6600

Last updated 2011-12-02

No results posted yet for this study

Summary

This is a review of previously published data from a large prostate cancer prevention study known as REDUCE. It is the investigators intention to review whether prostate specific antigen (PSA) velocity (change over time) will predict the presence of prostate cancer and its grade and stage (severity).

Conditions

Sponsors & Collaborators

  • University Urological Associates Inc.

    lead OTHER

Principal Investigators

  • Steven I Cohen, MD · University Urological Associates Inc.

Eligibility

Min Age
50 Years
Max Age
74 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2012-04-30
Completion
2012-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01484808 on ClinicalTrials.gov